Nervinex (Brivudine)

Nervinex is a nucleoside analogue antiviral used to manage infections caused by varicella‑zoster virus.

• Herpes Zoster (shingles): reduces the duration and severity of rash and acute pain in adult patients.
• Varicella‑zoster virus infections: treats systemic infection and accelerates lesion healing.
• Immunocompromised adult patients with VZV infection: provides antiviral control where immune response is reduced.

• After oral administration, brivudine is phosphorylated by viral thymidine kinase to its monophosphate and subsequently to the triphosphate form. The triphosphate competitively inhibits viral DNA polymerase, blocking viral DNA synthesis and preventing replication of varicella‑zoster virus in infected cells.

Adverse reactions may occur with brivudine therapy and should be monitored.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.
• Fatigue: general feeling of tiredness.
• Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

• Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention.
• Hepatic enzyme elevation: monitor liver function tests.
• Hematologic abnormalities (e.g., thrombocytopenia, neutropenia): may need blood count monitoring.
• Renal impairment: worsening kidney function in susceptible patients.
• Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.

Before initiating therapy, clinicians should consider several safety measures.

• Assess renal function: adjust use in patients with impaired clearance.
• Monitor hepatic function: watch for liver enzyme changes.
• Avoid in patients with known hypersensitivity to brivudine or excipients.
• Use with caution in immunocompromised individuals: infection risk may be higher.
• Review concomitant medications: potential for drug interactions.
• Store at below 25°C: keep in the original pack, protect from moisture.

Brivudine may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid)

• 5‑Fluorouracil or capecitabine: increased toxicity due to metabolic interference.
• Other nucleoside analogues metabolized by the same pathway: risk of additive adverse effects.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR for possible anticoagulant effect alteration.
• Corticosteroids: may affect immune response, requiring infection surveillance.
• Immunosuppressants (e.g., cyclosporine): monitor for enhanced viral replication risk.
• Oral contraceptives: observe for reduced efficacy.
• Other antiviral agents: assess for competitive inhibition or additive toxicity.